2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

  • ID: 4527597
  • Report
  • 50 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Albireo AB
  • CymaBay Therapeutics
  • FF Pharma
  • Genkyotex
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • MORE
Primary biliary cirrhosis (PBC) is a long term chronic and autoimmune disease in which the bile ducts are inflamed and gradually destroyed. This results in built of bile in the liver, resulting in damage to the liver. The rare disease has limited treatment options with FDA approving obeticholic acid plus ursodeoxycholic acid as a single therapy.

Over 25 companies and universities are focusing on developing treatment options for Primary biliary cirrhosis.

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Primary biliary cirrhosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Primary biliary cirrhosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Primary biliary cirrhosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Albireo AB
  • CymaBay Therapeutics
  • FF Pharma
  • Genkyotex
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • MORE
1.1 List of Figures
1.2 List of Tables

2 Primary biliary cirrhosis (PBC) Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Primary biliary cirrhosis (PBC) Pipeline Snapshot
2.3 Primary biliary cirrhosis (PBC) Pipeline by Phase
2.4 Primary biliary cirrhosis (PBC) Pipeline by Company
2.5 Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action

3 Primary biliary cirrhosis (PBC)- Company Wise Pipeline Analysis
  • Albireo AB
  • Arena Pharmaceuticals
  • CymaBay Therapeutics
  • Enanta Pharmaceuticals
  • FF Pharma
  • Genfit
  • Genkyotex
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • KAN Research Institute
  • NGM Biopharmaceuticals
  • Novartis
  • Phenex Pharmaceuticals
  • Retrophin
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Tiziana Life Sciences
  • Virobay Inc
  • Zydus Cadila
4 Primary biliary cirrhosis (PBC) R&D Pipeline Snapshots
  • Drug wise Pipeline Details
  • Therapeutic Candidate Name
  • Originator
  • Co-Developer/ License Partner
  • Orphan Drug Designation
  • Development Phase
  • Mechanism of Action
  • Current Status
  • Ongoing Clinical Trial Details
5 Recent Developments in Primary biliary cirrhosis (PBC) Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018
Figure 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

1.2 List of Tables
Table 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018
Table 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018
Table 3: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018
Table 4: Albireo AB Primary biliary cirrhosis Pipeline, May 2018
Table 5: Arena Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 6: CymaBay Therapeutics Primary biliary cirrhosis Pipeline, May 2018
Table 7: Enanta Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 8: FF Pharma Primary biliary cirrhosis Pipeline, May 2018
Table 9: Genfit Primary biliary cirrhosis Pipeline, May 2018
Table 10: Genkyotex Primary biliary cirrhosis Pipeline, May 2018
Table 11: GlaxoSmithKline Primary biliary cirrhosis Pipeline, May 2018
Table 12: Intercept Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 13: KAN Research Institute Primary biliary cirrhosis Pipeline, May 2018
Table 14: NGM Biopharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 15: Novartis Primary biliary cirrhosis Pipeline, May 2018
Table 16: Phenex Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 17: Retrophin Primary biliary cirrhosis Pipeline, May 2018
Table 18: Suzhou Zelgen Biopharmaceutical Co Ltd Primary biliary cirrhosis Pipeline, May 2018
Table 19: Tiziana Life Sciences Primary biliary cirrhosis Pipeline, May 2018
Table 20: Virobay Inc Primary biliary cirrhosis Pipeline, May 2018
Table 21: Zydus Cadila Primary biliary cirrhosis Pipeline, May 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Albireo AB
  • Arena Pharmaceuticals
  • CymaBay Therapeutics
  • Enanta Pharmaceuticals
  • FF Pharma
  • Genfit
  • Genkyotex
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • KAN Research Institute
  • NGM Biopharmaceuticals
  • Novartis
  • Phenex Pharmaceu
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll